このエントリーをはてなブックマークに追加
ID 61429
JaLCDOI
FullText URL
75_1_15.pdf 2.2 MB
Author
Katsui, Kuniaki Department of Proton Beam Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons
Ogata, Takeshi Department of Radiology, Iwakuni Clinical Center
Tada, Akihiro Department of Radiology, Okayama Diagnostic Imaging Center
Sugiyama, Soichi Department of Radiology, Okayama University Hospital
Yoshio, Kotaro Department of Radiology, Okayama University Hospital
Kuroda, Masahiro Department of Radiological Technology, Graduate School of Health Sciences, Okayama University ORCID Kaken ID publons researchmap
Kiura, Katsuyuki Allergy and Respiratory Medicine, Okayama University Hospital ORCID Kaken ID publons researchmap
Maeda, Yoshinobu Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
Toyooka, Shinichi General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Hiraki, Takao Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID publons researchmap
Kanazawa, Susumu Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID publons
Abstract
The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-radiotherapy (CCRT) with cisplatin/docetaxel. Cases involving definitive CCRT were reviewed retrospectively, and the maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. The relationships between these PET parameters and prognosis were analyzed. MTV and TLG were significant predictors of distant metastasis-free survival (DMFS) (p = 0.0003 and 0.0005, respectively) and progression-free survival (PFS) (p = 0.001 and 0.0007, respectively). The three-year DMFS rates in patients with low and high MTV were 13.3% and 64.6%, respectively, and the corresponding values in those with low and high TLG were 13.3% and 65.2%, respectively. The three-year PFS rates in patients with low and high MTV were 13.3% and 57.8%, respectively, and the corresponding values in patients with low and high TLG were 13.3% and 57.8%, respectively. However, MTV and TLG were not predictors of local control or overall sur-vival. We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT. Our findings contradict the findings of previous reports and warrant further research to validate them.
Keywords
volumetric positron emission tomography parameters
distant metastasis-free survival
chemoradiotherapy
cisplatin/docetaxel
non-small cell lung cancer
Amo Type
Original Article
Published Date
2021-02
Publication Title
Acta Medica Okayama
Volume
volume75
Issue
issue1
Publisher
Okayama University Medical School
Start Page
15
End Page
23
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2021 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
reference
Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K and Tanimoto M: Phase III trial comparing docetaxel and cis-platin combination chemotherapy with mitomycin, vindesine, and cispla-tin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol (2010) 28: 3299-3306.
Na F, Wang J, Li C, Deng L, Xue J and Lu Y: Primary tumor standard-ized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol (2014) 9: 834-842.
Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Chung JK, Kim EE and Lee DS: Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging (2015) 42: 241-251.
Im HJ, Bradshaw T, Solaiyappan M and Cho SY: Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? Nucl Med Mol Imaging (2018) 52: 5-15.
Grootjans W, Usmanij EA, Oyen WJ, van der Heijden EH, Visser EP, Visvikis D, Hatt M, Bussink J and de Geus-Oei LF: Perfor mance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy. Radiother Oncol (2016) 119: 473-479.
Salavati A, Duan F, Snyder BS, Wei B, Houshmand S, Khiewvan B, Opanowski A, Simone CB, 2nd, Siegel BA, Machtay M and Alavi A: Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging (2017) 44: 1969-1983.
Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M and Hoshino T: Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Eur J Radiol (2012) 81: 4179-4184.
Cremonesi M, Gilardi L, Ferrari ME, Piperno G, Travaini LL, Timmerman R, Botta F, Baroni G, Grana CM, Ronchi S, Ciardo D, Jereczek-Fossa BA, Garibaldi C and Orecchia R: Role of interim (18)F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review. Eur J Nucl Med Mol Imaging (2017) 44: 1915-1927.
Ogata T, Katsui K, Yoshio K, Ihara H, Katayama N, Soh J, Kuroda M, Kiura K, Maeda Y, Toyooka S and Kanazawa S: Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer. Acta Med Okayama (2018) 72: 507-513.
Katsui K, Ogata T, Watanabe K, Katayama N, Kuroda M, Kiura K, Hiraki T, Maeda Y, Toyooka S and Kanazawa S: Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters. Cancer Medicine (2020) (Epub ahead of print).
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Ozguroglu M and Investigators P: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med (2017) 377: 1919-1929.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Ozguroglu M and Investigators P: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med (2018) 379: 2342-2350.
Tsujino K, Hashimoto T, Shimada T, Yoden E, Fujii O, Ota Y, Satouchi M, Negoro S, Adachi S and Soejima T: Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. J Thorac Oncol (2014) 9: 983-990.
Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA and Velcheti V: Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest (2017) 152: 271-281.
Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C and Evans WK: 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst (2007) 99: 1753-1767.
Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Gregoire V, Thorwarth D, Fidarova E, Paez D, Chiti A and Hanna GG: PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol (2015) 116: 27-34.
Henson JW, Ulmer S and Harris GJ: Brain tumor imaging in clinical tri-als. AJNR Am J Neuroradiol (2008) 29: 419-424.
Boellaard R, Krak NC, Hoekstra OS and Lammertsma AA: Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med (2004) 45: 1519-1527.
Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH and Kim BT: Volume-based parameters of (18)F-fluorodeoxyglucose posi-tron emission tomography/computed tomography improve outcome pre-diction in early-stage non-small cell lung cancer after surgical resection. Ann Surg (2013) 257: 364-370.
Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H and Li B: Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med (2014) 55: 1584-1590.
Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM and Choi JY: Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. AJR Am J Roentgenol (2015) 205: 623-628.
Higashi K, Matsunari I, Ueda Y, Ikeda R, Guo J, Oguchi M, Tonami H and Yamamoto I: Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med (2003) 17: 1-14.
Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R and Milas L: Effect of docetaxel on the therapeutic ratio of fractionated radio-therapy in vivo. Clin Cancer Res (1999) 5: 4191-4198.
Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ and Miles KA: Non-small cell lung cancer: histopathologic correlates for texture parame-ters at CT. Radiology (2013) 266: 326-336.
Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, Marsden P, Ahmad S and Landau D: Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and sur-vival after chemoradiotherapy? J Nucl Med (2013) 54: 19-26.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Jr., Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F and Brahmer JR: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373: 1627-1639.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cis-platin plus gemcitabine with cisplatin plus pemetrexed in chemothera-py-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 26: 3543-3551.
Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI and Johnson DH: Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol (2009) 27: 1405-1412.
Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD and Chang JY: Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys (2010) 77: 357-366.
Rades D, Douglas S, Huttenlocher S, Rudat V, Veninga T, Stalpers LJ, Basic H, Karstens JH, Hoskin PJ, Adamietz IA and Schild SE: Validation of a score predicting post-treatment ambulatory status after radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys (2011) 79: 1503-1506.